Compare Gogoro Inc (GGR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs Zimmer Biomet Holdings Inc — how do they compare? Gogoro Inc trades at $3.15 (market cap $56.21M), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 301.5× Gogoro Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| GGR | ZBH | |
|---|---|---|
Market Cap | $56.21M | $16.95B |
Volume | 14,026 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.15 | $103.98 |
52-Week Low | $2.20 | $79.58 |
Typical Hold Time | 14 Days | 89 Days |
Enterprise Value | $342.65M | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gogoro (GGR) trades at $3.15, up 5.35% today, but faces bearish technical signals and weak profitability, with a net loss of $79.97M in 2025. Revenue grew modestly to $281.48M, yet margins remain negative. Recent news highlights board changes and a $61.8M equity investment, signaling internal restructuring efforts. The stock shows oversold conditions with an RSI of 27.68, but moving averages indicate a downtrend.
The outlook is cautious due to persistent losses and high debt-to-asset ratio of 60%, though low valuation ratios (P/S 0.16, P/B 0.5) may attract value investors. Risks include execution challenges and competitive pressures. Analysts are neutral with 100% hold ratings, reflecting uncertainty about near-term turnaround.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
